Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2024 | The challenge of treating BPDCN in a resource-limited setting

Astghik Voskanyan • 15 Jun 2024

EHA 2024

Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Astghik Voskanyan, MD, Immune Oncology Research Institute (IMMONC), Yerevan, Armenia, discusses a case of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who was treated in a resource-limited setting. The patient, unable to access tagraxofusp or undergo allogeneic stem cell transplantation (alloSCT), unfortunately passed away. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Treatment results of the tagraxofusp cohort of the BPDCN international registry

Treatment results of the tagraxofusp cohort of the BPDCN international registry

Astghik Voskanyan • 9 Dec 2024

Advancing the understanding of BPDCN through international collaboration

Advancing the understanding of BPDCN through international collaboration

Astghik Voskanyan • 15 Jun 2024

Related Videos

Refining the diagnosis and classification of CMML

Refining the diagnosis and classification of CMML

Guillermo Montalban-Bravo et al. • 20 Sep 2025

Improving the diagnosis of amyloidosis: advice that can be applied in practice

Improving the diagnosis of amyloidosis: advice that can be applied in practice

Gareth Morgan • 18 Sep 2025

Ongoing research in gray zone lymphoma

Ongoing research in gray zone lymphoma

Kieron Dunleavy • 4 Sep 2025

Insights into gray zone lymphoma: a rare subtype of NHL

Insights into gray zone lymphoma: a rare subtype of NHL

Kieron Dunleavy • 4 Sep 2025